Convergence begins Phase II of analgesic drug for LSR pain
This article was originally published in Scrip
Executive Summary
Convergence Pharmaceuticals has started a Phase II, proof of concept study investigating its state-dependent sodium channel blocker, CNV1014802, for treating pain associated with lumbosacral radiculopathy (LSR).